Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.70 |
| ▸ | KDR | P35968 | 9/20 | 0.70 |
| ▸ | KIF5B | P33176 | 1/20 | 0.62 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 7/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323193 | 0.89 | ABL1 (0.58) | RETFGFR1KDRABL1KIT | |
| SCHEMBL31474783 | 0.89 | ABL1 (0.76) | RETFGFR1KDRKIF5BCCDC6 | |
| SCHEMBL21843575 | 0.89 | ABL1 (0.76) | RETFGFR1KDRKIF5BCCDC6 | |
| Vamotinib SCHEMBL15789568 | 0.85 | ABL1 (0.80) | RETFGFR1KDRCCDC6ABL1 | |
| SCHEMBL14306277 | 0.85 | FGFR1 (0.69) | FGFR1KDRABL1KIT | |
| Vamotinib SCHEMBL29441255 | 0.85 | ABL1 (0.80) | RETFGFR1KDRCCDC6ABL1 | |
| SCHEMBL21843685 | 0.84 | RET (0.68) | RETFGFR1KDRKIF5BCCDC6 | |
| SCHEMBL24283204 | 0.83 | FGFR1 (0.73) | RETFGFR1KDRKIF5BCCDC6 | |
| Vamotinib SCHEMBL19475244 | 0.83 | ABL1 (0.76) | RETFGFR1KDRCCDC6ABL1 | |
| SCHEMBL21843537 | 0.83 | ABL1 (0.77) | RETFGFR1KDRKIF5BCCDC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089599-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2022-03-24 | — | — | US | disclosed |
| WO-2020053812-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089599-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | NADK, NAMPT, NME2 | RET 183/4885FGFR1 320/4885KDR 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.